Related Experiment Video
Updated: Sep 19, 2025
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
A novel anticancer candidate, coumarin-3-carboxamide derivative inhibits cell proliferation and migration in
Sevide Sencan1, Hulya Celik Onar2
1Department of Medical Biology, Faculty of Medicine, Bilecik Seyh Edebali University, Bilecik, Turkey.
Abstract:
Breast cancer is one of the leading cancer types in terms of morbidity and mortality worldwide. Although developing technology, early diagnosis and treatment opportunities provide positive contributions to the treatment of breast cancer, research on new drugs that are less toxic to healthy cells, safer and more effective for cancer cells, increasing the quality of life of the patient is still ongoing. Coumarin and its derivatives have been shown great interest to develop safer and more effective anticancer drugs. Therefore, we investigated the anticancer activity of novel coumarin-3-carboxamide derivative 3i in MDA-MB-231 cells. We found that coumarin-3-carboxamide derivative 3i inhibited cell proliferation, colony formation and migration. However, coumarin-3-carboxamide derivative 3i did not induce apoptosis and autophagy. Consequently, our findings suggest for the first time that novel coumarin-3-carboxamide 3i has anticancer activity and may be an important drug candidate for the treatment of triple-negative breast cancer. Further investigations are required to elucidate its impact on breast cancer.
Insights
A novel coumarin derivative, 3i, shows significant anticancer activity by inhibiting proliferation, colony formation, and migration in breast cancer cells. This compound may offer a promising new therapeutic option for triple-negative breast cancer.
Area of Science:
- Oncology
- Medicinal Chemistry
Background:
- Breast cancer remains a leading cause of cancer morbidity and mortality globally.
- Research is actively seeking novel anticancer drugs with improved efficacy and reduced toxicity.
- Coumarin derivatives are recognized for their potential in developing safer and more effective anticancer agents.
Purpose of the Study:
- To investigate the anticancer potential of a novel coumarin-3-carboxamide derivative, specifically compound 3i.
- To evaluate the effects of compound 3i on MDA-MB-231 breast cancer cells.
Main Methods:
- Assessment of cell proliferation inhibition.
- Colony formation assays were performed.
- Cell migration assays were conducted.
- Apoptosis and autophagy induction were analyzed.
Main Results:
- Compound 3i demonstrated significant inhibition of MDA-MB-231 cell proliferation.
- The derivative effectively suppressed colony formation and cell migration.
- Notably, compound 3i did not induce apoptosis or autophagy in the tested cells.
Conclusions:
- Novel coumarin-3-carboxamide derivative 3i exhibits promising anticancer properties.
- Compound 3i shows potential as a drug candidate for treating triple-negative breast cancer.
- Further research is warranted to fully understand its mechanism and therapeutic impact.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:15Drugs that Stabilize Microtubules